Sign In
Buy NXTC
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026
NextCure Reports First Quarter 2021 Financial Results
05:15pm, Thursday, 06'th May 2021
BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine
A Trio of Net Current Asset Value Stock Picks
12:35pm, Tuesday, 13'th Apr 2021
Short-term investors may want to have a look at these businesses
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
08:30am, Saturday, 10'th Apr 2021
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
04:05pm, Wednesday, 07'th Apr 2021
BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
04:05pm, Tuesday, 02'nd Mar 2021
BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure to Host Virtual R&D Update Event on March 4, 2021
04:15pm, Friday, 26'th Feb 2021
BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
Los Angeles, California--(Newsfile Corp. - February 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, I
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.
Dr. Han Myint Appointed as NextCure's Chief Medical Officer
04:05pm, Thursday, 14'th Jan 2021
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
The 10 Worst Performing Stocks of 2020
07:30am, Tuesday, 29'th Dec 2020
These companies are eager to say good riddance to the year that was.
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure”
NextCure Provides Updates on NC318 Clinical Program
07:05am, Thursday, 17'th Dec 2020
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
04:05pm, Monday, 23'rd Nov 2020
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class act
New York, New York--(Newsfile Corp. - November 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between Novem
